Excellent
Fully Aligned
Patient Risk:
Low
Summary
The response asserts that the “Risk of thyroid C-cell tumors” claim is supported and it aligns with the provided FDA label content (Boxed Warning and Section 5.1, plus related contraindications and adverse reactions). No contradictions or unsupported claims were made relative to the supplied label excerpts.
Category Scores
Accurate Statements
Risk of thyroid C-cell tumors is supported by the FDA label.
Supported by Boxed Warning and Section 5.1 describing dose- and duration-dependent thyroid C-cell tumors in rats and stating unknown human relevance.
The label ties the thyroid C-cell tumor risk to contraindications in patients with personal or family history of MTC or MEN 2.
Section 4 contraindications and Section 5.1 counseling reference this risk.
The label discusses counseling about symptoms of thyroid tumors and uncertainty about the value of routine monitoring (serum calcitonin and/or thyroid ultrasound).
Section 5.1 and Boxed Warning include both symptom counseling and uncertainty about routine monitoring.
Thyroid C-cell tumors are reflected as a serious adverse reaction in the label.
Section 6 lists 'Risk of Thyroid C-cell Tumors' as a serious adverse reaction.
Carcinogenicity findings in rats show thyroid C-cell adenomas (and combined adenomas/carcinomas).
Section 13.1 includes increases in thyroid C-cell adenomas and adenomas/carcinomas combined in rats.
Unsupported Statements
Contradictions
Important Omissions
The response does not quote or explicitly mention that the boxed warning/human relevance statement uses the phrasing 'It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including MTC, in humans' (it is implicitly covered).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response only evaluates label support for a safety claim and does not provide dosing, instructions, or new clinical recommendations beyond what the label excerpts already state.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement
Optionally include direct quotation-level references to the boxed warning/Section 5.1 human-uncertainty sentence, but the current assessment is already consistent with the provided excerpts.